Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Agios Pharmaceuticals Inc before investing.

In this article, we go over a few key elements for understanding Agios Pharmaceuticals Inc’s stock price such as:

• Agios Pharmaceuticals Inc’s current stock price and volume
• Why Agios Pharmaceuticals Inc’s stock price changed recently
• Upgrades and downgrades for AGIO from analysts
• AGIO’s stock price momentum as measured by its relative strength

About Agios Pharmaceuticals Inc (AGIO)

Before we jump into Agios Pharmaceuticals Inc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.

Want to learn more about Agios Pharmaceuticals Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc’s Stock Price as of Market Close

As of May 28, 2024, 4:00 PM, CST, Agios Pharmaceuticals Inc’s stock price was $38.81.

Agios Pharmaceuticals Inc is up 23.21% from its previous closing price of $31.50.

During the last market session, Agios Pharmaceuticals Inc’s stock traded between $31.00 and $33.46. Currently, there are 56.38 million shares of Agios Pharmaceuticals Inc stock available for purchase.

Unfortunately, Agios Pharmaceuticals Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Agios Pharmaceuticals Inc Stock Price History

Agios Pharmaceuticals Inc’s (AGIO) price is currently up 19.42% so far this month.

During the month of May, Agios Pharmaceuticals Inc’s stock price has reached a high of $39.70 and a low of $31.00.

Over the last year, Agios Pharmaceuticals Inc has hit prices as high as $35.50 and as low as $19.80. Year to date, Agios Pharmaceuticals Inc’s stock is up 38.21%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Agios Pharmaceuticals Inc Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 24, 2024, there were 0 analysts who downgraded Agios Pharmaceuticals Inc’s stock and 7 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Agios Pharmaceuticals Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Agios Pharmaceuticals Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Agios Pharmaceuticals Inc’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Agios Pharmaceuticals Inc (AGIO) by visiting AAII Stock Evaluator.

Relative Price Strength of Agios Pharmaceuticals Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 24, 2024, Agios Pharmaceuticals Inc has a weighted four-quarter relative price strength of -1.64%, which translates to a Momentum Score of 61 and is considered to be Strong.

Want to learn more about how Agios Pharmaceuticals Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Agios Pharmaceuticals Inc Stock Price: Bottom Line

As of May 28, 2024, Agios Pharmaceuticals Inc’s stock price is $38.81, which is up 23.21% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Agios Pharmaceuticals Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.